<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210914052469N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-06</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>"Evaluation of the effect of boron on kidney stones"</public_title>
      <acronym></acronym>
      <scientific_title>The effect of boron supplementation on nutritional status, kidney stone size, improvement of clinical symptoms and some of the serum and urine biomarkers in patients with nephrolithiasis: a randomized, double-blind, placebo-controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58730</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sampling is simple and available and the randomization tool will be random allocation software that in addition to simple randomization, this software will be able to random allocation by block method ( randomization Block) 
and randomly sequence the supplement or placebo. First, patients are blocked according to sex and then using block randomization method and blocks of four will be divided into two groups of intervention and placebo. To hide random allocation or not specify the type of intervention before assigning a person to a specific group, opaque sealed envelopes with random sequences will be used, in which each of the random sequences created on a card will be used. It is registered and the cards are placed in the letter envelopes in order. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. At the beginning of the registration of participants, according to the order of entry of participants, according to the order of entry of eligible participants to study, one of the envelopes is opened in order and the assigned group of the participant is revealed, Blinding description: 60 eligible patients will be randomly assigned to one of the intervention or control groups based on the blocks created by the random allocation  software. The generated random sequence is kept in a safe place and  performed by an independent third party who is blind to the trial during the study.</study_design>
      <phase>3</phase>
      <hc_freetext>kidney stone.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Boron citrate, dose: 5 mg per capsule, number of times: twice a day, time of use: 2 months, Manufacturer: Nutrition Research Center and School of Pharmacy,Tabriz University of Medical Sciences. Intervention 2: Intervention group 2: Sodium tetrahydroborate, dose: 5 mg per capsule,  number of times: twice a day, time of use: 2 months, Nutrition Research Center and School of Pharmacy,Tabriz University of Medical Sciences. Intervention 3: Control group: corn starch, dosage: 5 mg per capsule, number of times:  twice a day, time of use: 2 months, Nutrition Research Center and School of Pharmacy,Tabriz University of Medical Sciences.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will be confidential but the results of the study will be published based on the article

When:
The access period starts 6 months after the results are published

To whom:
The data will be available only to researchers working in academic and scientific institutions

Conditions:
The use of data is permitted for use in scientific research

Where to obtain:
To receive data by email, refer to ostadrahimi@tbzmed.ac.ir

How to obtain:
Requests should be emailed to ostadrahimi@tbzmed.ac.ir and information will be provided to the applicant within two weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Gita Vousoughi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.64, Farvardin Alley.,North Khajeh Nasir Ave</address>
        <city>Maragheh</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5516946418</zip>
        <telephone>+98 41 3746 1910</telephone>
        <email>gitvous@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Ostad Rahimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nutrition and Food Science, Attar Neyshabouri Ave., Golgasht Ave., Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3746 1910</telephone>
        <email>ostadrahimi@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with kidney stones in the age range of 20-65 years and willing to cooperate</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age under 20 and over 65 years
Pregnancy
Breastfeeding
Cardiovascular disease
Bile stone
Kidney failure
Cancer
Benign prostatic hyperplasia (BPH)
Hypothyroidism or hyperthyroidism
Urinary tract infection
Estrogen therapy
Egular use of vitamin supplements and herbal teas and Alcohol consumption</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Calculus of kidney and ureter</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Boron citrate, dose: 5 mg per capsule, number of times: twice a day, time of use: 2 months, Manufacturer: Nutrition Research Center and School of Pharmacy,Tabriz University of Medical Sciences.</i_keyword>
      <i_keyword>Intervention group 2: Sodium tetrahydroborate, dose: 5 mg per capsule,  number of times: twice a day, time of use: 2 months, Nutrition Research Center and School of Pharmacy,Tabriz University of Medical Sciences.</i_keyword>
      <i_keyword>Control group: corn starch, dosage: 5 mg per capsule, number of times:  twice a day, time of use: 2 months, Nutrition Research Center and School of Pharmacy,Tabriz University of Medical Sciences.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Kidney stone size. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Ultrasound.</prim_outcome>
      <prim_outcome>Improve clinical symptoms. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Anthropometric indicators include: weight, height, waist circumference, hip circumference. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Weight is measured using a Seca calibrated scale with an accuracy of 0.1 kg and with a minimum of clothing in the early morning in the form of fasting and measuring height, waist circumference and hip circumference using a tape measure with an accuracy of 0.1 cm.</prim_outcome>
      <prim_outcome>Serum levels of ionized calcium, phosphorus, uric acid, urea, creatinine and alkaline phosphatase. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: At the beginning and end of the study, fasting blood samples will be taken from all participants after 8-12 hours of fasting in the central laboratory of Maragheh. Determination of serum level of the studied variables is done according to the relevant protocol. Also, part of the serum sample is stored in a freezer at -70 degrees.</prim_outcome>
      <prim_outcome>Urine analysis (measurement of citrate and oxalate and urinary calcium and general urinalysis). Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: At the beginning and end of the study, random urine samples will be taken from all participants in Maragheh Central Laboratory and urine analysis will be performed.</prim_outcome>
      <prim_outcome>Body composition measurements include fat mass, lean body mass, total body water. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Using the BIA (Bioelectric Impedance Analyser) device, fasting (10-12  hours fasting) hs done.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-25</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>third house from the left, Oval dead end from the right,  Ghaem Alley, Etihad Alley, 20 meters from Etihad Alley, Pasdaran St Maraghe East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
